Results 141 to 150 of about 47,532 (242)

Suicide Deaths in People With Bipolar Disorder: Characteristics and Treatments at Time of Death

Bipolar Disorders, Volume 27, Issue 7, Page 527-537, November 2025.
ABSTRACT Objectives This study aimed to compare suicide deaths in those with or without bipolar disorder (BD), taking into particular consideration the degree to which treatment at the time of death, according to toxicology data, reflects evidence‐based pharmacotherapy.
Ayal Schaffer, Prudence Po Ming Chan, Vera Yu Men, Rosalie Steinberg, Rachel HB. Mitchell, Gin Malhi, Lakshmi N. Yatham, Mark Sinyor   +7 more
wiley   +1 more source

Preparation and <em>In-vitro</em> Evaluation of Gastroretentive Bupropion Hydrochloride Tablets

, 2012
Farnaz Fouladi, SA Mortazavi
openalex   +2 more sources

Olanzapine Attenuates Cue-elicited Craving for Tobacco

, 2004
Rationale: Recent biological conceptualizations of craving and addiction have implicated mesolimbic dopamine activity as a central feature of the process of addiction. Imaging, and pharmacological studies have supported a role for dopaminergic structures
Hutchinson, Kent E, Niaura, Raymond, Pickworth, Wallace B, Rutter Goodworth, Marie-Christine, Sobik, Laura, Swift, Robert   +5 more
core  

Valbenazine Sprinkle: An Alternative Formulation of Valbenazine for Oral Administration in Patients With Dysphagia

Clinical and Translational Science, Volume 18, Issue 11, November 2025.
ABSTRACT Valbenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment of tardive dyskinesia and Huntington's chorea. Dysphagia, pill aversion, and fear of swallowing are common in patients with these conditions. A new valbenazine sprinkle capsule, to be swallowed whole or the granule contents sprinkled onto soft food,
Nagdeep Giri, Roland Jimenez, Linda Rees, Alexander Mar, Ali Bristow, Mello Hebert, Jessica Maynard‐Scott, Hui Zhang, Satjit Brar   +8 more
wiley   +1 more source

Cardiovascular and kidney outcomes of GLP‐1 receptor agonists in adults with obesity: A target trial emulation study

Diabetes, Obesity and Metabolism, Volume 27, Issue 11, Page 6527-6536, November 2025.
Abstract Aims Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) provide cardiovascular and renal benefits in type 2 diabetes, but their real‐world effects in individuals with obesity without diabetes are unclear. This study aimed to evaluate the cardiovascular and kidney outcomes of GLP‐1RAs versus other anti‐obesity medications (AOMs) in adults ...
Huilin Tang, Yiwen Lu, Bingyu Zhang, Ting Zhou, Dazheng Zhang, Jiajie Chen, Yong Chen, David A. Asch, Yong Chen   +8 more
wiley   +1 more source

A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.

New England Journal of Medicine, 1999
Cott, L. J., Eischow, Itchell, N. A., Ides, Tephen, R. I., Ennard, Rlene, H. R., Ughes, Tevens, S. S., mith, Avid, D. M., Aughton, Imberli, Oan, Ichael, F. C., Iore, Imothy, B. B., Aker   +25 more
semanticscholar   +1 more source

ECT seizure parameter modulation with bupropion: a pilot study

, 2019
Nicholas Mischel, Gopalkumar Rakesh, G. Falcone-Gunderson, A Anderson, Dana D. Copeland, Steven T. Szabo, Richard D. Weiner   +6 more
openalex   +2 more sources

Bupropion overdose as a clinically significant confounder of the neurological examination [PDF]

, 2020
Ranier Reyes, Stephen A. Figueroa
openalex   +1 more source

Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial

JAMA Internal Medicine, 2018
Neal L Benowitz, A. Pipe, R. West, J. T. Hays, S. Tonstad, T. McRae, D. Lawrence, L. St Aubin, R. Anthenelli   +8 more
semanticscholar   +1 more source

Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)

Diabetes, Obesity and Metabolism, Volume 27, Issue 11, Page 6691-6704, November 2025.
Abstract Aims In this first interim analysis of the SCORE study, we investigated the risk of major adverse cardiovascular events (MACE) among individuals with atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity but without diabetes who initiated semaglutide 2.4 mg in real‐world settings.
Kim G. Smolderen, Carlos Mena‐Hurtado, Zhenxiang Zhao, Wojciech Michalak, Mads Faurby, B. Gabriel Smolarz, Mikhail N. Kosiborod, Jinlin Song, Yan Chen, Joanna Boland, Michael G. Nanna   +10 more
wiley   +1 more source